ライフサイエンスコーパス: matrix metalloproteinase 2

1 d increases in the elastin-degrading enzyme, matrix metalloproteinase 2.

2 ail1, plasminogen activator inhibitor 1, and matrix metalloproteinase 2.

3 ated with reduction of the metalloproteinase matrix metalloproteinase 2.

4 y cell migration through upregulation of pro-matrix metalloproteinase 2.

5 egulators C-terminal tensin-like protein and matrix metalloproteinase 2.

6 with cellular retinol-binding protein 1 and matrix metalloproteinase 2.

7 increased fibrosis and altered expression of matrix metalloproteinase-2.

8 and metastasis and inhibited the activity of matrix metalloproteinase-2.

9 ation sphingolipid G-protein receptor-1, and matrix metalloproteinase-2.

10 oproteinase inducer), to activate Akt1/2 and matrix metalloproteinase-2.

11 stant to breakdown by both collagenase D and matrix metalloproteinase-2.

12 trix metalloproteinase-2/tissue inhibitor of matrix metalloproteinase-2.

13 d beta3 integrins, and the production of pro-matrix metalloproteinase-2.

14 tracellular signal-regulated kinase 1/2, and matrix metalloproteinase-2.

15 17.8 [14.1-22.8] ng/mL) were higher, and for matrix metalloproteinase-2 (188 [155.5-230.6] ng/mL) low

16 r, double knockouts of apolipoprotein E with matrix metalloproteinase 2, 3, 7, 9, 12, and 13 have mor

17 ion of exogenous metalloproteases, including matrix metalloproteinases 2, 3, 8, 9, 12, and 13 and agg

18 , along with early upregulated expression of matrix metalloproteinases-2, -3, -9, -13, -14, and their

19 or necrosis factor-alpha; interleukin-6; and matrix metalloproteinases-2, -3, and -9.

20 reased expression of messenger RNAs encoding matrix metalloproteinase-2, -9, and -12, and cathepsins

21 tions in strial expression of mRNAs encoding matrix metalloproteinases-2, -9, -12, and -14.

22 y decreased by pharmacological inhibition of matrix metalloproteinase 2/9 activity.

23 lution in vivo using a fluorescent probe for matrix metalloproteinase-2/9 activity, fluorescein isoth

24 changes appear to be caused by increases in matrix metalloproteinase-2/9 secretion and transforming

25 sion was associated with increased levels of matrix metalloproteinase-2/9 transcripts.

26 eHsp90 promoted cell motility in an ERK and matrix metalloproteinase-2/9-dependent manner, and shift

27 Although activation of matrix metalloproteinase-2/-9 exhibited little change, t

28 actor (EGF) receptor, and (ii) expression of matrix metalloproteinase 2, a pro-invasive factor for tu

29 Furthermore, matrix metalloproteinase-2, a downstream target of beta-

30 nd was associated with the downregulation of matrix metalloproteinase-2, a known FoxM1 target.

31 aphy indicated increased secretion of active matrix metalloproteinase-2, a mediator of cell migration

32 As fibrillar type I collagen promotes pro-matrix metalloproteinase 2 activation by membrane type 1

33 cultures with 14G2a mAb showed decreases in matrix metalloproteinase-2 activation, a process regulat

34 Blockade of TFPI-2 suppressed matrix metalloproteinase-2 activation, and, therefore, T

35 lar CypA are required for ROS generation and matrix metalloproteinase-2 activation.

36 at correlated with significant decreased pro-matrix metalloproteinase-2 activation.

37 asphyxiated neonates and is associated with matrix metalloproteinase-2 activation.

38 beta responses, but inhibited leptin-induced matrix metalloproteinase-2 activation.

39 nds and is required for motility by inducing matrix metalloproteinase 2 activity, but phospho-extrace

40 se 1 messenger RNA expression, and increased matrix metalloproteinase 2 activity.

41 pendent mitochondrial Ca(2+) uptake promotes matrix metalloproteinase-2 activity and cell motility by

42 ese aneurysms and is associated with reduced matrix metalloproteinase-2 activity and diminished plasm

43 fter aortic cross-clamp release to determine matrix metalloproteinase-2 activity and troponin I level

44 cycline-treated piglets had lower myocardial matrix metalloproteinase-2 activity compared with contro

45 wed EGCG inhibits IL-6/soluble IL-6R-induced matrix metalloproteinase-2 activity in RA synovial fibro

46 ycline group (p = 0.01), and the increase of matrix metalloproteinase-2 activity in the placebo group

47 h cardiopulmonary bypass, it reduced cardiac matrix metalloproteinase-2 activity in these patients.

48 ndary to edema, we found that suppression of matrix metalloproteinase-2 activity is sufficient to abr

49 demonstrate elevated PI3K/Akt signaling and matrix metalloproteinase-2 activity that culminates in e

50 ith cardiopulmonary bypass, increased atrial matrix metalloproteinase-2 activity was inversely correl

51 Cardiac 72-kDa matrix metalloproteinase-2 activity was lower upon reper

52 Myocardial matrix metalloproteinase-2 activity was quantified by ge

53 addition, aortic macrophage infiltration and matrix metalloproteinase-2 activity were reduced in apoE

54 ancreatic cancer cells have reduced level of matrix metalloproteinase-2 activity, a secreted protease

55 n kinase C activation, actin polymerization, matrix metalloproteinase-2 activity, and astrocytoma mot

56 ymographic analysis and quantified by active matrix metalloproteinase-2 activity, as well as apoptosi

57 radiation concomitant with the inhibition of matrix metalloproteinase-2 activity, down-regulation of

58 crotaline-induced matrix metalloproteinase-9/matrix metalloproteinase-2 activity.

59 proteinase-1 (TIMP-1) expression and reduced matrix metalloproteinases-2 activity and collagen degrad

60 sulted in the upregulation of genes, such as matrix metalloproteinase-2, alkaline phosphatase, and tr

61 sed expression and proteolytic activities of matrix metalloproteinase-2, an enzyme that releases angi

62 mals (P < 0.05), resulting in a reduction of matrix metalloproteinase 2 and 9 activity in resolvin-tr

63 s markers for cell proliferation, as well as matrix metalloproteinase 2 and 9 for invasion.

64 on, extracellular matrix reorganization, and matrix metalloproteinase 2 and hyaluronic acid productio

65 Upregulation of matrix metalloproteinase 2 and proinflammatory cytokines

66 a) gene and protein expression and decreased matrix metalloproteinase 2 and tissue inhibitor of matri

67 ons with half-maximal inhibition (IC(50)) of matrix metalloproteinase- 2 and -9 (MMP-2 and -9).

68 TSP1) repeats are CCN1 degradome products by matrix metalloproteinase-2 and -14.

69 f ARF1 and Arfaptin2 leading to secretion of matrix metalloproteinase-2 and -7.

70 myocardial collagen content and accentuated matrix metalloproteinase-2 and -9 activity.

71 ardial fibrosis, downregulated expression of matrix metalloproteinase-2 and -9 and decreased gelatina

72 xplained by changes in mRNA of TGF-beta1 and matrix metalloproteinase-2 and -9 but was linked to decr

73 complex directly induced gene expression of matrix metalloproteinase-2 and -9 in vitro, which requir

74 Enzyme zymography showed attenuated matrix metalloproteinase-2 and -9 up-regulation post-MI

75 ssue growth factor, fibronectin, collagen-1, matrix metalloproteinase-2 and -9), enhanced cell death

76 tor stimulation increased activation of both matrix metalloproteinase-2 and -9.

77 Expression of matrix metalloproteinase-2 and 9 (MMP-2 and 9), tissue i

78 -1 signals, transcripts for the AP-1 target, matrix metalloproteinase-2 and associated invasive behav

79 Patients with HFpEF showed higher matrix metalloproteinase-2 and C-terminal propeptide of

80 egulation in expression of interleukin 8 and matrix metalloproteinase-2 and estrogen-induced increase

81 ine called S-SDF-1(S4V) that is resistant to matrix metalloproteinase-2 and exopeptidase cleavage but

82 lls with a trend for decreased expression of matrix metalloproteinase-2 and increased expression of t

83 RAD001 also attenuated the expression of matrix metalloproteinase-2 and inhibited the invasivenes

84 creased Matrigel invasiveness, and decreased matrix metalloproteinase-2 and matrix metalloproteinase-

85 In addition to inhibiting matrix metalloproteinase-2 and matrix metalloproteinase-

86 ow-mediated dilation of the brachial artery, matrix metalloproteinase-2 and matrix metalloproteinase-

87 structure content, the col 2 domain of human matrix metalloproteinase-2 and the kringle 2 domain of h

88 ls via reduced transcriptional activities of matrix metalloproteinase-2 and urokinase-type plasminoge

89 tility of prostate tumor cells by activating matrix metalloproteinases 2 and 9 (MMP2 and MMP9) in vit

90 -derived growth factor D, Pdgfrb, Itga2, and matrix metalloproteinases 2 and 9 expression in aortic l

91 or dimerization, and increased expression of matrix metalloproteinases 2 and 9 in an EGF receptor-dep

92 expression was accompanied by an increase of matrix metalloproteinases 2 and 9 in mice treated with a

93 We also observed the activation of matrix metalloproteinases 2 and 9 upon CXCL12 stimulatio

94 xenografted with human tumor cells secreting matrix metalloproteinases 2 and 9, ACPPs bearing a far-r

95 ssion of urokinase plasminogen activator and matrix metalloproteinases 2 and 9, and increased podocyt

96 ificantly attenuated the increased levels of matrix metalloproteinases 2 and 9, chemokines (KC, TARC)

97 The expression and activity of matrix metalloproteinases 2 and 9, which participate in

98 protein kinase A, protein phosphatase-1, and matrix metalloproteinases 2 and 9.

99 a signaling pathway in a mechanism involving matrix metalloproteinases 2 and 9.

100 factor, urokinase plasminogen activator, and matrix metalloproteinases 2 and 9.

101 creased the tubulointerstitial expression of matrix metalloproteinases 2 and 9.

102 l growth factor (VEGF) A, interleukin-8, and matrix metalloproteinases-2 and -9 and had a high vascul

103 s (vascular endothelial growth factor, VEGF; matrix metalloproteinases-2 and -9), and nucleolin (a nu

104 ns COX-2, cyclin D1, cytosolic beta-catenin, matrix metalloproteinases-2 and -9, and vascular endothe

105 as striking reductions in the production of matrix metalloproteinases-2 and -9.

106 ntervening linker is cut by tumor-associated matrix metalloproteinases-2 and 9 (MMP2,9) or elastases.

107 ed by augmented expression of extracellular (matrix metalloproteinase-2) and intracellular (ubiquitin

108 MMP-2, BSP, and natural (tissue inhibitor of matrix metalloproteinase-2) and synthetic (ilomastat and

109 rowth factor beta1, collagen type 4 alpha 1, matrix metalloproteinase 2, and alpha-smooth muscle acti

110 otein levels; increased expression of SNAIL, matrix metalloproteinase 2, and integrin beta1; and incr

111 en, tissue inhibitor of metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase

112 eukin-1 receptor family member), galectin-3, matrix metalloproteinase-2, and collagen III N-terminal

113 reatment resulted in decreased expression of matrix metalloproteinase-2, and decreased vascularizatio

114 remodeling, collagen content, expression of matrix metalloproteinase-2, and increased levels of tiss

115 inase-1 promoter region, tissue inhibitor of matrix metalloproteinase-2, and tissue inhibitor of matr

116 pression of TGF-beta, collagen, fibronectin, matrix metalloproteinase-2, and tissue inhibitor of meta

117 nd reduced ECM turnover due to inhibition of matrix metalloproteinase 2 by EFEMP1(R345W) and C3a.

118 reased expression of metalloproteinase-9 and matrix metalloproteinase-2 by sinusoidal endothelial cel

119 tin and large amounts of collagen type I and matrix metalloproteinase-2, characteristic features of m

120 resistant to dipeptidylpeptidase IV/CD26 and matrix metalloproteinase-2 cleavage and delivered by nan

121 tant to both dipeptidylpeptidase IV/CD26 and matrix metalloproteinase-2 cleavage, was active in vitro

122 ion, cellular retinol-binding protein 1, and matrix metalloproteinase 2, compared to term and preterm

123 xidative stress, fibrosis, and intracellular matrix metalloproteinase 2 content.

124 epsin B and cathepsin L, tissue inhibitor of matrix metalloproteinase 2, cytochrome c oxidase, and al

125 With repair, matrix metalloproteinase-2 decreased to < or = 50% that

126 s, LAP cleavage is shown to be predominantly matrix metalloproteinase 2 dependent.

127 nregulation of bone morphogenesis protein 4, matrix metalloproteinase 2, endothelial plasminogen acti

128 Zymographic analysis revealed that matrix metalloproteinase-2 enzymatic activity was elevat

129 Matrix metalloproteinase 2 expression is observed associ

130 signal-regulated kinase 1/2 activation, and matrix metalloproteinase 2 expression, all of which are

131 Matrix metalloproteinase-2 expression and activation by

132 on with repressed elastin mRNA and increased matrix metalloproteinase-2 expression and activity, both

133 ing the PKC-Raf/MEK/ERK pathways controlling matrix metalloproteinase-2 expression and podosome forma

134 ndothelial growth factor, interleukin-8, and matrix metalloproteinase-2 expression levels, as well as

135 p38 MAPK induces matrix metalloproteinase-2 expression to cleave E-cadher

136 LV collagen synthesis and maturation, and matrix metalloproteinase-2 expression, were more importa

137 evels, reduced nitrosative stress, and lower matrix metalloproteinase-2 expression.

138 ERK pathway, resulting in down-regulation of matrix metalloproteinase-2 expression.

139 pression, and decreasing tissue inhibitor of matrix metalloproteinase-2 expression.

140 failed to induce alpha-smooth muscle actin, matrix metalloproteinase-2, fibronectin, and integrin-li

141 ix metalloproteinase 9 and 13 expression and matrix metalloproteinase 2 gelatinase activity were sign

142 wever, SDF-1 is cleaved by exopeptidases and matrix metalloproteinase-2, generating a neurotoxin impl

143 ors of IPAH patients secreted high levels of matrix metalloproteinase-2, had greater affinity for ang

144 , granulocyte colony-stimulating factor, and matrix metalloproteinase 2 in STZ-induced diabetic bone

145 vels in ESA-treated animals revealed reduced matrix metalloproteinase 2 in the borderzone (P<0.05), w

146 ell as enhanced synthesis of fibronectin and matrix metalloproteinase-2 in a PAR-2- and ERK1/2-depend

147 upregulation of beta-catenin, vimentin, and matrix metalloproteinase-2 in hepatoma cells.

148 ter activity and the collagenase activity of matrix metalloproteinase-2 in human melanoma cells, resu

149 e-9 and a later, lower-magnitude increase of matrix metalloproteinase-2 in the liver.

150 atrix metalloproteinase inhibitor, prevented matrix metalloproteinase-2-induced troponin I cleavage i

151 extracellular matrix synthesis and decreased matrix metalloproteinase-2 levels as well as cell hypert

152 necrosis factor-alpha, interferon-gamma, and matrix metalloproteinase-2 levels.

153 characterization revealed that the levels of matrix metalloproteinase-2, matrix metalloproteinase-9,

154 Gelatin zymography indicated that matrix metalloproteinase 2 (MMP-2) and MMP-9 activities

155 invasion through the down-regulation of the matrix metalloproteinase 2 (MMP-2) and MMP-9 expression.

156 Matrix metalloproteinase 2 (MMP-2) contains three fibron

157 ascular endothelial growth factor (VEGF) and matrix metalloproteinase 2 (MMP-2) expression in brain c

158 We found that matrix metalloproteinase 2 (MMP-2) facilitated invasion

159 Activation of matrix metalloproteinase 2 (MMP-2) has been shown to pla

160 the following markers of collagen turnover: matrix metalloproteinase 2 (MMP-2), tissue inhibitor of

161 e 1 collagen (ICTP), collagen VI, desmosine, matrix metalloproteinase 2 (MMP-2), tissue inhibitor of

162 Fibroblasts constitutively express matrix metalloproteinase 2 (MMP-2), which specifically c

163 d and evaluated the biological properties of matrix metalloproteinase 2 (MMP-2)-responsive N-(2-hydro

164 novel markers such as HER2/neu, survivin and matrix metalloproteinase 2 (MMP-2).

165 ly related to increased expression of active matrix metalloproteinase 2 (MMP-2).

166 llular [3H]-proline incorporation, increased matrix metalloproteinase-2 (MMP-2) activity and protein,

167 c stimulus, which correlated with diminished matrix metalloproteinase-2 (MMP-2) activity by gelatin z

168 pithelial cells were found to have increased matrix metalloproteinase-2 (MMP-2) activity indicating t

169 Acquisition of matrix metalloproteinase-2 (MMP-2) activity is temporall

170 ype 1 matrix metalloproteinase (MT1-MMP) and matrix metalloproteinase-2 (MMP-2) activity, critical in

171 The present study assessed the role of matrix metalloproteinase-2 (MMP-2) and -9 in synapse los

172 Neutrophils may be an important source of matrix metalloproteinase-2 (MMP-2) and matrix metallopro

173 Matrix metalloproteinase-2 (MMP-2) and MMP-9 mRNA increa

174 y and invasion, the latter via activation of matrix metalloproteinase-2 (MMP-2) and MMP-9.

175 Matrix metalloproteinase-2 (MMP-2) and transforming grow

176 eloping bone and atherosclerotic plaque, and matrix metalloproteinase-2 (MMP-2) are coordinated and i

177 Levels of the proteinase matrix metalloproteinase-2 (MMP-2) are highly increased

178 ic binding to cancer cells is facilitated by matrix metalloproteinase-2 (MMP-2) as evidenced by reduc

179 howed 3-5-fold increase in the expression of matrix metalloproteinase-2 (MMP-2) as well as other inva

180 Human matrix metalloproteinase-2 (MMP-2) contains an array of

181 ases cellular invasive potential by inducing matrix metalloproteinase-2 (MMP-2) expression and activi

182 nase activities, as well as higher levels of matrix metalloproteinase-2 (MMP-2) expression and activi

183 In addition, matrix metalloproteinase-2 (MMP-2) expression in the iri

184 Matrix metalloproteinase-2 (MMP-2) expression is often u

185 adhesion molecule-1 (PECAM-1) and decreased matrix metalloproteinase-2 (MMP-2) expression.

186 The expression of matrix metalloproteinase-2 (MMP-2) has been linked with

187 Matrix metalloproteinase-2 (MMP-2) has pivotal role in t

188 scular endothelial growth factor (VEGF), and matrix metalloproteinase-2 (MMP-2) in vivo and in vitro.

189 Selective small-interfering RNA to matrix metalloproteinase-2 (MMP-2) inhibited endothelium

190 Matrix metalloproteinase-2 (MMP-2) is a protease related

191 Matrix metalloproteinase-2 (MMP-2) is the dominant elast

192 FRNK-expressing cells exhibited decreased matrix metalloproteinase-2 (MMP-2) mRNA levels and MMP-2

193 Matrix metalloproteinase-2 (MMP-2) plays an essential ro

194 Matrix metalloproteinase-2 (MMP-2) plays important roles

195 Matrix metalloproteinase-2 (MMP-2) rates of hydrolysis f

196 Matrix metalloproteinase-2 (MMP-2) was increased by Nox1

197 gamma) treatment showed that the activity of matrix metalloproteinase-2 (MMP-2) was increased in lung

198 Interactions of matrix metalloproteinase-2 (MMP-2) with native and denat

199 induce limited gelatinase activity in latent matrix metalloproteinase-2 (MMP-2) without removal of th

200 TG2 regulates the expression and function of matrix metalloproteinase-2 (MMP-2), a critical mediator

201 bility to inhibit cell-surface activation of matrix metalloproteinase-2 (MMP-2), a potent mediator of

202 Sensors showed a negligible response to matrix metalloproteinase-2 (MMP-2), a protease which may

203 More IL-8, VEGF, matrix metalloproteinase-2 (MMP-2), and microvessel dens

204 of metalloproteinases-2 (TIMP-2), activates matrix metalloproteinase-2 (MMP-2), and stimulates cell

205 ession profoundly affected the expression of matrix metalloproteinase-2 (MMP-2), basic fibroblast gro

206 We find that expression of matrix metalloproteinase-2 (MMP-2), known in other syste

207 branching and increased levels of Cyclin D1, matrix metalloproteinase-2 (MMP-2), matrix metalloprotei

208 collagen, transforming growth factor-beta 1, matrix metalloproteinase-2 (MMP-2), MMP-13, and interfer

209 TGF-beta1), connective tissue growth factor, matrix metalloproteinase-2 (MMP-2), MMP-14, endoglin (EN

210 egulation of FoxM1 reduced the expression of matrix metalloproteinase-2 (MMP-2), MMP-9 and vascular e

211 ipeptidyl peptidase-IV, neutrophil elastase, matrix metalloproteinase-2 (MMP-2), MMP-9, and cathepsin

212 omerular gelatinase expression, specifically matrix metalloproteinase-2 (MMP-2), MMP-9, and MMP-14, w

213 0/CCL6 decreased the levels of mRNA encoding matrix metalloproteinase-2 (MMP-2), MMP-9, and tissue in

214 Numbers of infiltrating cells and levels of matrix metalloproteinase-2 (MMP-2), nitric oxide (NO), a

215 pha), stromal cell derived factor-1 (SDF-1), matrix metalloproteinase-2 (MMP-2), vascular endothelial

216 scular endothelial growth factor (VEGF), and matrix metalloproteinase-2 (MMP-2), which are upregulate

217 2 (VEGFR2) signaling and decreased levels of matrix metalloproteinase-2 (MMP-2), with no effect on le

218 ensor, we have demonstrated the detection of matrix metalloproteinase-2 (MMP-2)-an important gelatina

219 okinase-type plasminogen activator (uPA) and matrix metalloproteinase-2 (MMP-2).

220 B/urokinase-type plasminogen activator (uPA)/matrix metalloproteinase-2 (MMP-2).

221 Previous work has shown that BSP can bind to matrix metalloproteinase-2 (MMP-2).

222 asion, including cyclooxgenase-2 (COX-2) and matrix metalloproteinase-2 (MMP-2).

223 Golgi network leading to an inactive form of matrix metalloproteinase-2 (MMP-2).

224 x receptor on the surface of glioma cells as matrix metalloproteinase-2 (MMP-2).

225 n the activation of paxillin, NF-kappaB, and matrix metalloproteinase-2 (MMP-2).

226 In vitro, Meg3 regulated the production of matrix metalloproteinase-2 (MMP-2).

227 gelatinase activity that was confirmed to be matrix metalloproteinase-2 (MMP-2; gelatinase A) by West

228 Matrix metalloproteinase-2 (MMP-2; gelatinase A) is know

229 e genes regulated by them, ie, the genes for matrix metalloproteinases 2 (MMP-2) and 9 (MMP-9) and ti

230 ha1(I) and alpha1(IV) collagens, TIMP-1, and matrix-metalloproteinase 2 (MMP-2) mRNAs.

231 matrix degradation and cytokine processing (matrix metalloproteinase 2 [MMP-2] and MMP-9), and the i

232 nism by which LRP1 induces the expression of matrix metalloproteinase 2 (MMP2) and MMP9 and thereby p

233 oactivator and formed complexes with PEA3 on matrix metalloproteinase 2 (MMP2) and MMP9 promoters to

234 (rhEPO) significantly increased secretion of matrix metalloproteinase 2 (MMP2) and MMP9.

235 Then we identified matrix metalloproteinase 2 (MMP2) as a direct target of

236 The inhibition mechanism of matrix metalloproteinase 2 (MMP2) by the selective inhib

237 Matrix metalloproteinase 2 (MMP2) can associate with int

238 ormonal induction of fat body remodeling and Matrix metalloproteinase 2 (MMP2) expression in the fat

239 reviously, we demonstrated the importance of matrix metalloproteinase 2 (MMP2) for airway egression o

240 ng is essential for the proper activation of matrix metalloproteinase 2 (Mmp2) for follicle rupture.

241 ms in the estrogen receptor alpha (ESR1) and matrix metalloproteinase 2 (MMP2) genes are associated w

242 st time that alphavbeta6 selectively induces matrix metalloproteinase 2 (MMP2) in vitro in multiple p

243 (TSP2)-null mice results from an increase in matrix metalloproteinase 2 (MMP2) levels.

244 lly-active laminin-111 fragment generated by matrix metalloproteinase 2 (MMP2) processing, which is h

245 Matrix metalloproteinase 2 (MMP2) was shown to be expres

246 We show here that matrix metalloproteinase 2 (MMP2), as part of an interle

247 or beta1 (Tgf-beta1), collagen 1a1 (Col1A1), matrix metalloproteinase 2 (Mmp2), cytokeratin 19, alpha

248 ed to the PDL-MSCs, and higher expression of matrix metalloproteinase 2 (MMP2), interleukin (IL)-6, i

249 lay increased expression of Slug, Twist, and matrix metalloproteinase 2 (MMP2), loss of E-cadherin, a

250 Matrix metalloproteinase 2 (MMP2), which degrades Type I

251 on subverted lung T cell priming by inducing matrix metalloproteinase 2 (MMP2), which impaired the ac

252 ich contained a polyethylene glycol (PEG), a matrix metalloproteinase 2 (MMP2)-sensitive peptide link

253 therapeutic, a nanopreparation composed of a matrix metalloproteinase 2 (MMP2)-sensitive self-assembl

254 , and its transcriptional targets, including matrix metalloproteinase 2 (MMP2).

255 forming growth factor-beta1 (TGF-beta1), and matrix metalloproteinase 2 (MMP2).

256 ADP(+) and ATP contents (spectrophotometry), matrix metalloproteinase-2 (MMP2) activities (gelatin zy

257 p, and Reck could suppress the expression of matrix metalloproteinase-2 (Mmp2) and Mmp9, which could

258 Of these, matrix metalloproteinase-2 (MMP2) and tissue inhibitor o

259 assays, the expression of the gene encoding matrix metalloproteinase-2 (MMP2) in GBM cell lines grow

260 f retinal progenitor cells induced increased matrix metalloproteinase-2 (MMP2) secretion, partly from

261 enhances the activity but not expression of matrix metalloproteinase-2 (MMP2), the target substrate

262 , tissue plasminogen activator (tPA), and/or matrix metalloproteinase-2 (MMP2).

263 describing the proteolysis of collagen I by matrix metalloproteinases 2 (MMP2) and membrane type 1 m

264 ulocyte-colony-stimulating factor) and MMP2 (matrix metalloproteinase 2), MMP3, MMP9 and MMP13.

265 ha(+)/CD44(+)/matrix metalloproteinase-14(+)/matrix metalloproteinase-2(+) myofibroblasts, which secr

266 mice were unable to induce OX40 and OX40L by matrix metalloproteinase-2 on splenic dendritic cells.

267 ctivation of the PI3K-integrin-linked kinase-matrix metalloproteinase 2 pathway was detected mainly i

268 Inhibition of matrix metalloproteinase-9 and matrix metalloproteinase-2 prevents the development of s

269 ndothelial growth factor A, which stimulates matrix metalloproteinase 2 production and the invasive m

270 then recruit and activate Akt2, resulting in matrix metalloproteinase-2 production.

271 surface MT1-MMP-catalyzed activation of pro-matrix metalloproteinase-2 (proMMP-2) required proper gl

272 red for DDR2-mediated transactivation of the matrix metalloproteinase-2 promoter.

273 growth-regulated oncogene (GRO), CX3CL1, and matrix metalloproteinase-2 protein and cyclooxygenase-2

274 n deposition, together with increased latent matrix metalloproteinase-2 protein and reduction in smoo

275 Matrix metalloproteinase-2 proteolyzes intracellular pro

276 ted the promoter and collagenase activity of matrix metalloproteinase 2, resulting in decreased invas

277 Immunostaining for matrix metalloproteinase-2 revealed concurrent reduction

278 PRL-3 also enhanced matrix metalloproteinase-2 secretion and cellular invasi

279 el invasion and migration, and a decrease in matrix metalloproteinase-2 secretion by HUVEC.

280 transformed cells secreted a large amount of matrix metalloproteinase-2 that specifically degraded tu

281 Urinary levels of matrix metalloproteinase 2, the enzyme responsible for a

282 inase-1 promoter region, tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) and tissue inhibitor

283 Tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) belongs to a small f

284 of angiogenesis known as tissue inhibitor of matrix metalloproteinase-2 (TIMP-2), characterized for i

285 MT1-MMP and low amount of issue inhibitor of matrix metalloproteinase-2 (TIMP-2), their expression wa

286 enable disengagement of tissue inhibitor of matrix metalloproteinase 2 (TIMP2) and tumor invasion.

287 Type 1 MMP (MT1-MMP) and tissue inhibitor of matrix metalloproteinase 2 (TIMP2).

288 previously inhibited by tissue inhibitor of matrix metalloproteinase-2 (TIMP2).

289 ng (procollagen type III N-terminal peptide, matrix metalloproteinase-2, tissue inhibitor of matrix m

290 ibrosis, myocyte apoptosis, and the ratio of matrix metalloproteinase-2/tissue inhibitor of matrix me

291 he expression of genes encoding cathepsin D; matrix metalloproteinase 2; urokinase plasminogen activa

292 odulating expression of genes, such as IL-8, matrix metalloproteinase-2, vascular endothelial growth

293 ed for the in vitro and in vivo detection of matrix metalloproteinases-2 via a MMP-2-specific peptide

294 Decreased expression of matrix metalloproteinase 2 was also observed in the impl

295 Moreover, TGF-beta1-mediated induction of matrix metalloproteinase-2 was selectively dependent on

296 Further, matrix metalloproteinase-2 was up regulated within these

297 of the extracellular matrix-degrading enzyme matrix metalloproteinase-2 were increased by thymosin be

298 ptor, vascular cell adhesion molecule 1, and matrix metalloproteinase 2, were significantly associate

299 of fibroblast activation markers, including matrix metalloproteinase 2, were significantly increased

300 n of phosphatidylserine (PS), annexin A6 and matrix metalloproteinase-2, which converts exosomes into